23 February 2018

EU PhD training network

SAFER is the first European research platform to gain a molecular understanding and improve selectivity in the stimulation of the serotonin 5-HT2A receptor – the primary target for many CNS-related disorders and hallucinogens. SAFER will design and prepare ligands for the receptor, generate and cross-interpret pharmacology and crystallographic data, and construct computational mechanistic models and databases.

The SAFER network comprises five PhD students in pharmacology, chemistry, crystallography, computational drug design and scientific database development; first receiving 1-1,5 years joint training at the University of Copenhagen (Denmark) followed by industrial research at Enamine (Kiev, Ukraine) or SARomics (Lund, Sweden).

SAFER is coordinated by Jesper Kristensen at the University of Copenhagen who leads a chemistry group that has developed serotonin 5-HT2A receptor ligands being used as tracers for human brain imaging for diagnosis and evaluation of treatments.

SAFER logo